Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolemia

European Journal of Preventive Cardiology

Volumn 6, Issue 6, 1999, Pages 399-403

  Rubinstein, Ardon ^a   Maritz, Frans J ^f   Soule, Steven G ^g   Markerl, Arie ^b   Chajek Shaul, Tova ^c   Maislos, Maximo ^d   Tal, Sharon ^e   Stolero, Dan ^e  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e Pharma Clinical Ltd   (Israel)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

cerivastatin; coronary heart disease; efficacy; hypercholesterolaemia; safety; type 2 diabetes

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MUSCLE ENZYME; NITRATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PYRIDINES; RISK FACTORS;

EID: 0033378807     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/204748739900600607     Document Type: Article

References (19)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–2038.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 1: 1373–1376.
3. Rosengren A, Welin L, Tsipogrianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabetic men: a general population study. BMJ 1984; 299: 1127–1131.
4. Malmberg M, Ryden L. Myocardial infarction in patients with diabetes. Eur Heart J 1988; 9: 259–264.
5. Stern MP, Patterson JM, Haffner SM, Hazuda HP, Mitchell BD. Lack of awareness and treatment of hypeilipidemia in type II diabetes in a community survey. JAMA 1989; 262: 360–364.
6. Laakso M. Epidemiology of diabetic dyslipidemia. Diabetes Rev 1995; 3: 404–422.
7. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8–13.
8. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
9. Pyorala K, Pedersen TR, Kjekshus J, Faergemen O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–620.
10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009.
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laasko M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.
12. Stein E, Strecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR, The Cerivastatin Study Group. Cerivastatin, a new potent synthetic HMG CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997; 2: 7–16.
13. Stein E. Extending therapy options in treating lipid disorders - a clinical review of cerivastatin, a novel HMG CoA reductase in inhibitor. Drug 1998; 56(suppl 1): 25–31.
14. Stein E. Cerivastatin in primary hyperlipidemia - a multicenter analysis of efficacy and safety. Am J Med 1998; 82: 40J–46J.
15. Tikkanen MJ, Laasko M, llmonen M, Helve E, Kaarsalo E, Kilkki E, et al Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998; 21: 477–481.
16. Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M. A multinational study of the effects of low dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Clin Cardiol 1994; 17: 558–562.
17. Raskin P, Ganda OP, Schwartz S, Willard D, Rosenstock J, Lodewick PA, et al Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am J Med 1995; 99: 362–369.
18. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 81–86.
19. Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96 (suppl 6A): 69S–S78.